Sanofi takes $250M hit after gamble on J&J E. coli vaccine ends in phase 3 failure
A year and a half after Sanofi swooped in on Johnson & Johnson’s dismantled vaccines unit to pick up an E.coli candidate, the asset has failed its phase 3 trial.
A year and a half after Sanofi swooped in on Johnson & Johnson’s dismantled vaccines unit to pick up an E.coli candidate, the asset has failed its phase 3 trial.
